UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Thiotepa-based autograft for primary central nervous system lymphoma

Haematologica (Roma), 2024-10, Vol.109 (10), p.3083-3084

2024

Volltextzugriff (PDF)

Differentiating central nervous system infection from disease infiltration in hematological malignancy

Scientific reports, 2022-09, Vol.12 (1), p.15805-10, Article 15805

2022

Volltextzugriff (PDF)

Author Correction: Differentiating central nervous system infection from disease infiltration in hematological malignancy

Scientific reports, 2022-12, Vol.12 (1), p.21009-21009, Article 21009

2022

Volltextzugriff (PDF)

EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S119-S122

2023

Volltextzugriff (PDF)

S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

HemaSphere, 2023-08, Vol.7 (S3), p.e2454568-n/a

2023

Volltextzugriff (PDF)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

HemaSphere, 2022-10, Vol.6 (Suppl), p.7-8

2022

Volltextzugriff (PDF)

230 A dog with a bone (marrow biopsy)

Journal of neurology, neurosurgery and psychiatry, 2019-12, Vol.90 (12), p.e58-e58

2019

Volltextzugriff (PDF)

Extending potentially curative options for older patients with PCNSL

The Lancet. Haematology, 2024-03, Vol.11 (3), p.e171-e173

2024

Volltextzugriff (PDF)

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.10316-10317

2022

Volltextzugriff (PDF)

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.302-302

2023

Volltextzugriff (PDF)

Peripheral T-cell lymphoma with bilateral ocular involvement

Indian journal of ophthalmology - case reports, 2024-04, Vol.4 (2), p.348-351

2024

Volltextzugriff (PDF)

Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.372-374

2022

Volltextzugriff (PDF)

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Blood, 2020-11, Vol.136 (Supplement 1), p.20-21

2020

Volltextzugriff (PDF)

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Blood, 2020-11, Vol.136 (Supplement 1), p.18-19

2020

Volltextzugriff (PDF)

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.1718-1718

2023

Volltextzugriff (PDF)

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Journal of clinical oncology, 2024-08

2024

Volltextzugriff (PDF)

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.2492-2492

2021

Volltextzugriff (PDF)

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.642-642

2021

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(70)

Publikationsform

Sprache

Englisch
(79)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Thiotepa-based autograft for primary central nervous system lymphoma

Differentiating central nervous system infection from disease infiltration in hematological malignancy

Author Correction: Differentiating central nervous system infection from disease infiltration in hematological malignancy

EXABS-231-ABCL The Treatment of Primary and Secondary CNS Lymphoma

S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

230 A dog with a bone (marrow biopsy)

Extending potentially curative options for older patients with PCNSL

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Peripheral T-cell lymphoma with bilateral ocular involvement

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Aktive Filter

Suchergebnisse filtern